“Three dimensional (3D) bioprinting is the utilization of 3D printing and 3D printing–like techniques to combine cells, growth factors, and biomaterials to fabricate biomedical parts that maximally imitate natural tissue characteristics” (Wikipedia). Bioprinting raises complex ethical and legal issues, at the intersection of law and technology.
Dr Marc Mimler‘s newly published book-chapter ‘Patenting Bioprinting-Technologies in the US and Europe: The Fifth Element in the Third Dimension’ canvasses the patentability of bioprinting technologies in the US and Europe. The chapter, co-authored by Marc Mimler together with Professor Timo Minssen (University of Copenhagen) was published in 3D Printing, Intellectual Property and Innovation: Insights from Law and Technology edited by Dr. Rosa Maria Ballardini (University of Lapland & Hanken), Prof. Marcus Norrgård (University of Helsinki) and Prof. Jouni Partanen (Aalto University).
